Objective. Failure of first-line anti-tumor necrosis factor (TNF) agents in in rheumatoid arthritis patients leads to decisions among second-line biologic agents. To better inform these decisions, the therapeutic effectiveness of rituximab is compared with other second-line biologic agents in this observational study. Methods. Between November 2011 and December 2014, study subjects were observed for 12 month periods. Patients with an inadequate response to initial anti-TNF agent received either rituximab or alternative anti-TNF agents (adalimumab/etanercept/infliximab) based on the preference of patients and physicians. The efficacy end point of this study was the change in 28-joint count Disease Activity Score (DAS28) at six and 12 months from baseline. Safety data were also collected. Results. Ninety patients were enrolled in the study. DAS28 at six months did not change significantly whether the patients were treated with rituximab or alternative anti-TNF agents in intention-to-treat analysis (n=34, −1.63±0.30 vs. n=31, −2.05±0.34) and standard population set analysis (n=31, −1.51±0.29 vs. n=24, −2.21±0.34). Similarly, the change in DAS28 at 12 months did not reach statistical significance (−1.82±0.35 in the rituximab vs. −2.34±0.44 in the alternative anti-TNF agents, p=0.2390). Furthermore, the incidences of adverse events were similar between two groups (23.5% for rituximab group vs. 25.8% for alternative anti-TNF agents group, p=0.7851). Conclusion. Despite the limitations of our study, switching to rituximab or alternative anti-TNF agents after failure of the initial TNF antagonist showed no significant therapeutic difference in DAS28 reduction. (J Rheum Dis 2017;24:227-235)
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by the progressive and irreversible destruction of joints [1] . According to the 2009 National Health and Nutrition Survey in Korea, the prevalence of RA was 1.9% in subjects aged ≥30 years and 4.3% in ≥65 [2] . While RA is less prevalent compared to other chronic diseases, it develops in relatively younger ages, causes severe disability and seriously inter- feres with daily activities [3, 4] . According to the 2009 National Health Insurance Statistical Yearbook, approximately 280 thousand patients were treated for RA yearly in Korea, incurring more than Korean Won 300 billion as direct treatment expenses [5] . The treatment goal for RA is to control pain with a minimum of side effects, delay disease progression, postpone development of joint damage and dysfunction as much as possible, and thereby preserve the quality of life [6] . During the past decades, great improvements have been achieved in the field of RA treatment with the emergence of biologic disease-modifying antirheumatic drugs including anti-tumor necrosis factor (anti-TNF) agents and their establishment in clinical practice [7] . Nonetheless, approximately one third of patients treated with first-line anti-TNF drugs failed to meet the American College of Rheumatology 20% response criteria, the minimum index for the effects of RA medication [8] [9] [10] [11] [12] . In addition, some patients experienced a gradual decrease in efficacy with long-term use or early discontinuation of TNF antagonists due to side effects [13] .
In case of treatment failure after the first-line anti-TNF agents, the second-line biologics including alternative anti-TNF agents or biologics with a different mechanism of action (e.g. interleukin-6 inhibitors [tocilizumab], B-cell depleting antibodies [rituximab] , or inhibitors of T-cell co-stimulation [abatacept]) are commonly used [14] . To date, however, no study has been conducted comparing the efficacy among the second-line biologics in Korea. Thus, the objective of this observational study was to investigate and compare the therapeutic effectiveness of rituximab (Mabthera Ⓡ ) and second-line biologic agents in RA patients after failure of the first-line TNF antagonists in the real clinical practice in Korea.
MATERIALS AND METHODS
This was a non-interventional, prospective and observational study. Between November 2011 and December 2014, patients using second-line biological agents for RA treatment were enrolled in 13 University Hospitals. The decision making related to the treatment strategy was made on the preference of patients and physicians without arbitrations. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients and local Institutional Review Boards approved the protocol. The inclusion criteria for this study were: (i) RA subjects aged over 20 years who were discontinued the first-line anti-TNF treatment owing to inadequate response or intolerance and (ii) initiated second-line biologics including either rituximab or alternative anti-TNF agents, different from the first anti-TNF one, within 6 weeks before participation of the study. The only exclusion criterion was subjects who participated in other clinical trials related to RA and received investigational products accord- ing to the protocol while being treated with the first or second-line biological agents.
Patients were classified into two groups according to the prescribed second-line biologic agents: rituximab vs. alternative anti-TNF agents (adalimumab, etanercept, infliximab). Demographic and clinical data were collected at the baseline and follow-ups were performed at 6 and 12 months. The primary endpoint of this study was the change in 28-joint count Disease Activity Score (DAS28) calculated with 3 variables including tender joint count, swollen joint count, and erythrocyte sedimentation rate (ESR) after 6 months. The secondary endpoint was the change in DAS28 after 12 months. Safety data including adverse events (AEs), adverse drug reactions (ADRs), and serious adverse events (SAEs) were also collected. ADRs were defined as AEs related to the medication and the relationship of AEs to each drug was assessed by the physicians. SAEs were defined as AEs presenting a significant hazard or side effect (e.g. any event that was fatal, life-threatening, required hospitalization, or resulted in persistent or significant disability) [15, 16] .
Statistical analyses were performed using a commercially available software package (SAS version 9.3 system; SAS Institute Inc., Cary, NC, USA). The intention-to-treat set (ITT set) included subjects who received at least one dose of the second-line biologics and had the primary endpoint results. The standard population set (SPS) consisted of subjects who maintained the second-line biological agents which were initially selected for 6 months among the ITT set. Two sample t-test was conducted to compare continuous variables between groups. Pearson's chi-square or Fisher's exact test was used to compare categorical variables. Analysis of covariance (ANCOVA) models was performed to compare the change of DAS28 at 6 and 12 months between groups. The DAS28 and rheumatoid factor (RF) status at baseline were included in the models as covariances. A p-value ＜0.05 was considered statistically significant.
RESULTS
A total of 90 patients were ultimately enrolled in the study. Among them, 46 (51.1%) patients received rituximab; 44 (48.9%) were treated by the second-line TNF antagonists including adalimumab (20 subjects), etanercept (13 subjects), and infliximab (11 subjects) after failure of the first-line anti-TNF treatment. After excluding 25 patients who failed to assess the primary outcome at 6 months, 34 were in the rituximab group, and 31 were in the alternative anti-TNF agents group in the ITT set. Three patients in the rituximab and 7 patients in the alternative anti-TNF agents were further excluded owing to change or discontinuation of the initial medication in the SPS set. Details of patient enrollment and study flow are shown in Figure 1 . The mean age of the rituximab group was 55.62±11.92 and the alternative anti-TNF agents group was 52.74±14.36 years. Majority of patients were female and non-smoker in both groups (73.5% and 76.5% in the rituximab group and 83.9% and 87.1% in the alternative anti-TNF agents, respectively). The baseline characteristics did not differ significantly between two groups (Table 1) . Table 2 demonstrates the pattern of prescription and the Change is difference between baseline and 6 months. DAS28: disease activity score in 28 joints, TNF: tumor necrosis factor, ITT: intention-to-treat, SPS: standard population set, SD: standard deviation, LS: least squares, SE: standard error. *Two sample t-test. † The p-values are based on analysis of covariance models with control for DAS28 and rheumatoid factor of baseline.
reason of medication change over the study period. Most of the patients received either adalimumab or eternacept as the initial anti-TNF treatment. The most common reason of discontinuation of the first treatment was loss of response over the time. After change of medication, 3 patients were discontinued their treatment due to no response in the rituximab group, while 5 were changed and 2 were suspended their medication in the alternative anti-TNF agents group at 6 months of follow-up. On the other hand, 24 out of 29 subjects (82.8%) in the rituximab group and 17 out of 21 (81.0%) in the alternative anti-TNF agents group maintained the second-line medications at 12 months of follow-up.
Changes in DAS28 at 6 and 12 months after using secondary biological agents treatment for each treatment group are presented in Tables 3 and 4 . After adjusting for DAS28 and RF status at baseline, changes in DAS28 at 6 months were −1.63±0.30 in the rituximab group and −2.05±0.34 in the alternative anti-TNF agents group in the ITT analysis which did not reach statistical significance (p=0.3037). The SPS analysis also showed no statistical difference (−1.51±0.29 in the rituximab vs. −2.21±0.34 in the alternative anti-TNF agents, p=0.0951). Similarly, change in DAS28 at 12 months did not significantly differ between two groups (−1.82±0.35 in the rituximab vs. −2.34±0.44 in the alternative anti-TNF agents, p=0.2390).
Since most of enrolled patients showed DAS28 high disease activity (＞5.1) at baseline, all patients can be classified as moderate response or no response according to European League Against Rheumatism (EULAR) response criteria based on DAS28 score. Moderate EULAR response after 6 months was noted in 64.7% and 77.4% in the rituximab group and the alternative anti-TNF group, respectively. Similarly, the EULAR moderate response The p-values are based on analysis of covariance models with control for DAS28 and rheumatoid factor of baseline. rate was not different between the rituximab group and the alternative anti-TNF agents (82.8% and 79.2%, respectively) at 12 months (Figure 2) . Table 5 summarizes the AEs during the study period. In the rituximab group, a total of 12 AEs (8/34 patients, 23.5%) were reported, while 15 AEs (8/31 patients, 25.8%) were observed in the alternative TNF antagonists group. Among all AEs, 5 AEs (4/34 patients, 11.8%) and 3 AEs (3/34 patients, 8.8%) in the rituximab group were classified as ADRs and SAEs, whereas 7 AEs (5/31 patients, 16.1%) were categorized into ADRs in the alternative anti-TNF agents group. The incidence of AEs, ADRs, and SAEs did not differ between two groups (p=0.7851 for AEs; p=0.8205 for ADRs; p=0.8330 for SAEs, respectively). The detail of AEs are presented in Table 5 .
DISCUSSION
For RA patients with deficient effects of or inadequate response to the first-line anti-TNF agent, the Korea Health Insurance Review & Assessment Service recommended changing the medication to another anti-TNF agents, rituximab, or abatacept. According to the UK National Institute for Health and Clinical Excellence guidelines, rituximab was preferentially recommended for these patients, mainly due to its excellent cost-effectiveness compared to other second-line biologics [17] . In addition, small observational studies conducted in Swiss reported a greater reduction in DAS28 by rituximab than other drugs [18, 19] . In this study, however, we found that the change in DAS28-ESR at 6, 12 months was similar, regardless of medications chosen. And Standard Population Set interim analysis also showed no statistical difference at 6 months.
There are several reasons for the conflicting results between the studies. The composition of the study population differ in each study. Although demographic profiles of the current study including age and gender dis- tribution were similar to previous studies as well as general epidemiologic data for RA [14, 20] , it is well known that the response to the medication is different depending on the race [21] . The number of previously administered anti-TNF agents also impacts the effects of later administered biologics in treating RA [22] [23] [24] . It is hard to draw a firm conclusion from the previous and current studies, due to their non-interventional design and relatively small number of patients.
In regard to the safety of the medications, the incidence of AEs, ADRs, and SAEs were not different between groups which was comparable to the results of previous studies [18, 19] . Except previously known anaphylactoid reaction or infection due to immunosuppression, additional unexpected serious adverse drug reactions were not observed [25] . As our study was a non-interventional observational study, there were several intrinsic limitations. First, unlike randomized controlled trials, the choice of the biologic agent was dependent on the preference of the patients and their attending physicians which meant that selection bias was inevitable. However, the baseline characteristics did not differ between two groups. Second, owing to the small number of patients enrolled, this study did not reach statistical power to detect the difference of efficacy between rituximab and alternative anti-TNF agents. Therefore, our study has some limitation to get the significant power to determine the effect size. Because there was more percentage of patients that dropped out in the anti-TNF agents group, it might have a bias to analyze the change of DAS28 only in the remaining group. There is a high probability that rituximab was shown to be more effective than the anti-TNF agents. Considering the baseline DAS28 was higher in rituximab group, the analysis of change in DAS28 at 12 months was conducted with ANCOVA with control for DAS28 and RF of baseline. Regard to baseline characteristics, there are limitation due to missing values of rheumatoid factor status and anti-citrullinated protein antibody status because of multicenter trial in character.
CONCLUSION
This 12 months follow-up observational study, which compared effectiveness in reducing disease activity of rituximab and alternative anti-TNF agents, shows no significant difference between two treatments. However, the findings of our study are expected to be utilized as basis of future clinical trials and development of treatment guidelines for RA patients in Korea.
